Two similar studies showed that the HER2-low expression evolved from primary to recurrent breast cancer (30) and between early and advanced-stage breast cancer (31), which indicated that a second biopsy might be necessary during the disease progression for suitable treatment options. Here, ERBB2 is linked to breast cancer.